PET for Alzheimer Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Alzheimer Disease+6 More
PET - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new PET scan to map tau pathology in the brains of people with Primary Progressive Aphasia. If successful, this could help researchers better understand and treat this disease.

Eligible Conditions
  • Alzheimer Disease
  • Alzheimer's Disease

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Alzheimer Disease

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 2 years

2 years
Tau levels in PPA participants

Trial Safety

Safety Progress

1 of 3

Other trials for Alzheimer Disease

Side Effects for

Safety Analysis Set
2%Injection Site Paraesthesia
2%Injection Site Pain
1%Injection Site Haematoma
This histogram enumerates side effects from a completed 2016 Phase 4 trial (NCT02681172) in the Safety Analysis Set ARM group. Side effects include: Injection Site Paraesthesia with 2%, Injection Site Pain with 2%, Injection Site Haematoma with 1%.

Trial Design

1 Treatment Group

AV-1451 Recipients
1 of 1
Experimental Treatment

70 Total Participants · 1 Treatment Group

Primary Treatment: PET · No Placebo Group · Phase 1

AV-1451 RecipientsExperimental Group · 2 Interventions: PET, 18F-AV-1451 · Intervention Types: Device, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PET
2009
Completed Phase 4
~700
Flortaucipir F-18
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,432 Previous Clinical Trials
769,467 Total Patients Enrolled
8 Trials studying Alzheimer Disease
45,784 Patients Enrolled for Alzheimer Disease
National Institute on Aging (NIA)NIH
1,380 Previous Clinical Trials
3,446,686 Total Patients Enrolled
310 Trials studying Alzheimer Disease
865,381 Patients Enrolled for Alzheimer Disease
Emily Rogalski, Ph.D.Principal Investigator - Northwestern University
Northwestern University
1 Previous Clinical Trials
95 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 29th, 2021

Last Reviewed: October 15th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.